XML 70 R54.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 23, 2017 | Sep. 21, 2016 | Mar. 01, 2016 | Dec. 31, 2017 | Nov. 30, 2017 | Sep. 30, 2017 | Jan. 31, 2017 | Aug. 31, 2016 | Apr. 30, 2016 | Nov. 30, 2015 | Aug. 31, 2015 | Mar. 31, 2015 | Jun. 30, 2014 | Feb. 29, 2012 | Jan. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2013 | Dec. 31, 2007 | Jul. 31, 2016 | Jul. 31, 2015
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 305,500,000 |  |  |  |  |  |
Liability related to refundable upfront payment |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | $ 12,500,000 |  |  |  |  |
Settlement Agreement with Allergan, Inc and Map Pharmaceuticals, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
License revenue received related to share of payments due |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,000,000 |  |  |  |  |  |
Gain on settlement agreement represents reimbursement of legal expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000 |  |  |  |  |  |
Nektar's [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nektar's [Member] | AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestones, royalties and sales milestones |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestones payment, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur. |  |  |  |  |  |
Revenue related to Phase 1 clinical development and drug development activities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,200,000 |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,900,000 |  |  |  |  |  |
Revenue related to license activities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,900,000 |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,600,000 |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,500,000 |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development and Drug Product Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 19,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,900,000 |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional development and regulatory milestones | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development milestones payments, to be received may be reduced under certain conditions | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development milestones payments, to be received will be reduced if conditions occur | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance payment from collaboration partner |  |  |  |  |  |  | $ 12,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Reagent Shipments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance payment from collaboration partner for reagent shipments |  |  |  |  |  |  | $ 10,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ophthotech Corporation [Member] | Minimum Purchase Requirement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance payment from collaboration partner |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,300,000 |  |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of remaining deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,000,000 |  |  |  |  |  |
Ophthotech Corporation [Member] | Fovista [Member] | Novartis Pharma AG [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,800,000 |  |  |  |  |  |  |  |  |  |  |
Bayer Healthcare LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |
Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |  |  |
Recognition of remaining deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,800,000 |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |
Development milestones achieved |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received under right to sublicense agreement |  |  |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocated consideration for ongoing supply obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |
Consideration received for right to sublicense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,000,000 |  |  |  |  |  |
Baxalta Incorporated [Member] | ADYNOVATE (Hemophilia) [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |  |
MAP Pharmaceuticals, Inc. [Member] | MAP-Allergan, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000 |  |  |  |  |  |  |  |  |
Allergan, Inc. [Member] | Settlement Agreement with Allergan, Inc and Map Pharmaceuticals, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment received under settlement agreement for relief of claims related to share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  | 14,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,200,000 |  |  |  |  |  |
AstraZeneca AB [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liability to AZ for DTC advertising payments |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 | $ 5,000,000
Reduction of revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (10,000,000) |  |  |  |
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 125,000,000 |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential contingent payments based on development events |  |  |  | 75,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
AstraZeneca AB [Member] | AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  | $ 28,000,000 |  |  |  |  |  |  |  |  | 4,600,000 | 33,000,000 |  |  |  |  |
Deferred revenue |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Upfront and milestone payments received by Our collaboration partner under sublicense arrangement |  |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner |  |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Refundable upfront payment paid |  |  |  | 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |  |
Liability related to refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |
Non-refundable portion of upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,500,000 |  |  |  |  |
Revenue recognized from upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,700,000 |  |  |  |  |
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of remaining deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,200,000 |  |  |  |  |  |
Roche [Member] | MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received for product delivered |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,600,000 |  |  |
Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 27,000,000 |  |  |  |  |  |  |  |  |  |
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |
Bristol-Myers Squibb [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Strategic collaboration agreement date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Feb. 13, 2018 |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of out-of-pocket costs reimbursed by partner |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments received for reimbursement of costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,800,000 |  |  |  |  |  |
License agreement exclusivity expiration date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Sep. 30, 2018 |  |  |  |  |  |
License agreement exclusivity negotiation period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 months |  |  |  |  |  |
Other [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 45,500,000 |  |  |  |  |  |
Deferred revenue |  |  |  | $ 2,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,900,000 |  |  |  |  |  |

X
- Definition Advance payment from collaboration partner. + References No definition available. + Details
Name: | nktr_AdvancePaymentFromCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Advance payment received from collaboration partner. + References No definition available. + Details
Name: | nktr_AdvancePaymentReceivedFromCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocated consideration for ongoing supply obligation. + References No definition available. + Details
Name: | nktr_AllocatedConsiderationForOngoingSupplyObligation
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Consideration received for product delivered. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForProductDelivered
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Consideration received for right to sublicense. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForRightToSublicense
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gain related to settlement agreement. + References No definition available. + Details
Name: | nktr_GainRelatedToSettlementAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase decrease in revenue. + References No definition available. + Details
Name: | nktr_IncreaseDecreaseInRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability to AZ for DTC advertising payments. + References No definition available. + Details
Name: | nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability for refundable upfront payment. + References No definition available. + Details
Name: | nktr_LiabilityForRefundableUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement exclusivity expiration date. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityExpirationDate
Namespace Prefix: | nktr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement exclusivity negotiation period. + References No definition available. + Details
Name: | nktr_LicenseAgreementExclusivityNegotiationPeriod
Namespace Prefix: | nktr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License revenue related to share of payments due. + References No definition available. + Details
Name: | nktr_LicenseRevenueRelatedToShareOfPaymentsDue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable portion of upfront payment. + References No definition available. + Details
Name: | nktr_NonRefundablePortionOfUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Paid for liability for refundable upfront payment. + References No definition available. + Details
Name: | nktr_PaidForLiabilityForRefundableUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment received under settlement agreement for relief of claims related to share + References No definition available. + Details
Name: | nktr_PaymentReceivedUnderSettlementAgreementForReliefOfClaimsRelatedToShare
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments received for reimbursement of costs. + References No definition available. + Details
Name: | nktr_PaymentsReceivedForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments received under rights to sublicense agreement. + References No definition available. + Details
Name: | nktr_PaymentsReceivedUnderRightsToSublicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received, if conditions occur. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received under certain conditions. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding Phase three development costs on an indication by indication basis borne. + References No definition available. + Details
Name: | nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of out of pocket costs to be reimbursed by partner. + References No definition available. + Details
Name: | nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in Phase 2 development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront milestones royalty and sales milestone payments from sublicense agreement retained by our collaboration partner. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontMilestonesRoyaltyAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent payments based on development events. + References No definition available. + Details
Name: | nktr_PotentialContingentPaymentsBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development and regulatory milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Recognition of remaining deferred revenue. + References No definition available. + Details
Name: | nktr_RecognitionOfRemainingDeferredRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory milestones payment, description. + References No definition available. + Details
Name: | nktr_RegualtoryMilestonesPaymentDescription
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized from upfront payment. + References No definition available. + Details
Name: | nktr_RevenueRecognizedFromUpfrontPayment
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue related to license activities. + References No definition available. + Details
Name: | nktr_RevenueRelatedToLicenseActivities
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue requiring delivery of multiple elements. + References No definition available. + Details
Name: | nktr_RevenueRequiringDeliveryOfMultipleElements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Strategic collaboration agreement date. + References No definition available. + Details
Name: | nktr_StrategicCollaborationAgreementDate
Namespace Prefix: | nktr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and milestone payments received by our collaboration partner under sublicense arrangement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedByOurCollaborationPartnerUnderSublicenseArrangement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_SettlementAgreementWithAllerganIncAndMAPPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_LicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_PhaseOneClinicalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_DrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_PhaseOneClinicalDevelopmentAndDrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_ReagentShipmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_MinimumPurchaseRequirementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_FovistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nktr_NovartisPharmaAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_MAPPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MAPCollaborationWithAllerganIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AllerganIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_DaiichiSankyoEuropeGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ONZEALDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_PEGASYSAndMIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |